MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.neuropharm.2025.110528

Медицинская библиотека · Neuropharmacology · 2025

The novel compound CP-10 suppresses microglia-mediated neuroinflammation and neutrophil chemotaxis and attenuates ischemic brain injury by targeting FPR1.

Dong Meng-Qi, Chen Yan, Wang Qing, Li Hui-Qin, Bai Ling-Yun, Cao Xiang, Xu Yun

СтатьяПеревод пока не подготовлен

Аннотация

Ischemic stroke represents a major neurological disorder characterized by significant morbidity, where neuroinflammation plays a central role in exacerbating cerebral injury. Following ischemic events, microglial activation and the subsequent infiltration of peripheral immune cells, particularly neutrophils, contribute to the disruption of the blood-brain barrier and amplify neuronal damage. In the present study, as a part of our ongoing screening experiment to evaluate the anti-inflammatory effects of new compounds, a novel compound, namely N-{2-[(7-chloro-4-oxo-4H-pyrido[1,2-a] pyrimidin-2-yl) methoxy] phenyl}-2,2-dimethylpropanamide (referred to as CP-10 in this study), to test whether it could target microglial activation and neutrophil chemotaxis, both critical contributors to ischemic brain injury. CP-10 exhibited no apparent cytotoxicity to primary microglia or neurons at concentrations up to 30 μM. Transcriptomic analysis revealed that CP-10 modulated a wide range of inflammatory and immune response genes, particularly those associated with neutrophil chemotaxis, such as Cxcl1, Cxcl2, Cxcl3, and Cxcl5. Mechanistically, CP-10 exerted its effects by interacting with formyl peptide receptor 1 (FPR1), a receptor involved in microglial activation and neutrophil recruitment. In vivo, CP-10 significantly reduced infarct volume and neurological deficits in a mouse model of middle cerebral artery occlusion (MCAO), accompanied by reduced neutrophil infiltration and microglial activation in the ischemic penumbra. Furthermore, CP-10 inhibited key inflammatory signaling pathways, including NF-κB and MAPK, downstream of FPR1 activation. These findings position CP-10 as a promising candidate for ischemic stroke therapy, targeting neuroinflammation and immune cell chemotaxis via FPR1 modulation.

Для цитирования: Dong Meng-Qi, Chen Yan, Wang Qing, Li Hui-Qin, Bai Ling-Yun, Cao Xiang, Xu Yun. The novel compound CP-10 suppresses microglia-mediated neuroinflammation and neutrophil chemotaxis and attenuates ischemic brain injury by targeting FPR1.. Neuropharmacology. 2025. DOI: 10.1016/j.neuropharm.2025.110528.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.